Condition: Alopecia Areata · Sponsor: Sun Pharmaceutical Industries, Inc.
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
This description comes directly from the study's public registry record.
Head Regulatory Affairs · 9122 66455645 · Clinical.Trial@sunpharma.com
Always discuss trial participation with your own doctor first.
| Total Skin And Beauty Dermatology Center | Birmingham, Alabama, United States | Recruiting |
| Avacare - Cct Research - Center For Dermatology And Plastic Surgery | Scottsdale, Arizona, United States | Recruiting |
| Dermatology Trial Associates | Bryant, Arkansas, United States | Recruiting |
| Kern Research Inc. | Bakersfield, California, United States | Recruiting |
| Center For Dermatology Clinical Research Inc. | Fremont, California, United States | Recruiting |
| Dermatology Research Associates | Los Angeles, California, United States | Recruiting |
| Palmtree Clinical Research | Palm Springs, California, United States | Recruiting |
| Paradigm Clinical Research - San Diego | San Diego, California, United States | Recruiting |
| Colorado Medical Research Center | Denver, Colorado, United States | Recruiting |
| Paradigm Clinical Research - Wheat Ridge | Wheat Ridge, Colorado, United States | Recruiting |
| D&H Doral Research Center | Doral, Florida, United States | Recruiting |
| Skin Care Research, Llc - Hollywood | Hollywood, Florida, United States | Recruiting |
+ 52 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07133308